43
Participants
Start Date
October 7, 2021
Primary Completion Date
August 11, 2025
Study Completion Date
August 11, 2025
Aerobic exercise
Participants with symptomatic knee osteoarthritis and depressive symptoms will be enrolled in a progressive walking program designed to reduce pain and disability and improve psychosocial health.
Duloxetine
Duloxetine is an FDA-approved selective serotonin and norepinephrine reuptake inhibitor antidepressant approved for the treatment of neuropathic pain in symptomatic knee osteoarthritis as well as depression in adults. Participants with symptomatic knee osteoarthritis and depressive symptoms will receive duloxetine to decrease pain and depression severity to enhance their ability to engage in aerobic exercise.
University of Maryland School of Medicine, Baltimore
National Institute on Aging (NIA)
NIH
University of Maryland, Baltimore
OTHER